New Triple-Threat vaccine aims to shield seniors from three winter viruses
NCT ID NCT06984094
First seen May 13, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study tests two new vaccines (SCB-1022 and SCB-1033) designed to protect against RSV, human metapneumovirus, and parainfluenza virus. Researchers will enroll 612 healthy adults aged 60-85 to check safety and immune response. The goal is to see if combining protection against these respiratory viruses in one shot is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fusion Clinical Research
Adelaide, Southern Australia, 5067, Australia
-
Linear Clinical Research
Perth, Western Australia, 6009, Australia
-
Paratus Clinical Research
Melbourne, Victoria, 3070, Australia
Conditions
Explore the condition pages connected to this study.